Glucose Disorders Associated with HIV and its Drug Therapy

Abstract

Spanish

French

OBJECTIVE:

To review the impact that factors such as HIV infection, antiretrovirals, and other commonly used drug therapies have on glucose metabolism in HIV-infected patients.

DATA SOURCES:

Pertinent literature was identified via a MEDLINE search from 1980 to April 2000 and through secondary sources (abstracts presented at recent scientific meetings, manufacturers' package inserts). The key words used were antiretroviral therapy, HIV infection, insulin resistance, and metabolic abnormalities. All information deemed relevant to evaluate the impact that HIV infection and drug therapy have on glucose metabolism in HIV-infected patients was included.

DATA SYNTHESIS:

The viral burden and stress that are present in HIV-infected patients elicit a complex hormonal and immunologic response that may alter various biochemical pathways, including glucose metabolism. Although rare before the era of potent antiretroviral therapy, insulin resistance has now been described as an important component of the lipodystrophy syndrome. The complex and multifactorial nature of glucose metabolism dysregulation makes management of hyperglycemia or diabetes mellitus challenging in HIV-infected patients. In such a context, a set of recommendations was developed to guide practitioners in assessing, treating, and monitoring hyperglycemia or diabetes mellitus in HIV-infected patients.

CONCLUSIONS:

Alterations of glucose metabolism observed in HIV-infected patients are more frequent since the introduction of potent antiretroviral therapy. Although the etiology of such abnormalities remains unknown, protease inhibitors and, to a lesser extent, nucleoside reverse transcriptase inhibitors are believed to participate in their pathogenic mechanisms. Because of similarities to the pathogenesis of diabetes mellitus, management of antiretroviral-induced hyperglycemia could follow that the recommendations of the American Diabetes Association, with special considerations for monitoring patients with HIV infection. Future studies of altered glucose metabolism in HIV-infected patients should focus on understanding the precise mechanism or causes of this complication so that preventive and therapeutic guidelines can be further evaluated.

Keywords

antiretroviral therapy human immunodeficiency virus hyperglycemia

Get full access to this article

View all access options for this article.

References

Kotler

Rosenbaum

Wang

Pierson

. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Syndr Human Retrovirol 1998;20:228–37.

Grinspoon

Bilezikian

. HIV disease and the endocrine system. N Engl J Med 1992;327:1360–5.

Grinspoon

. Metabolic complications of ARVT. Topics HIV Med 1999;(Oct):14–9.

Sellmeyer

Grunfeld

. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocrine Rev 1996;17:518–32.

Mhiri

Belec

Di Costanza

Georges

Gherardi

. The slim disease in African patients with AIDS. Trans R Soc Trop Med Hyg 1992;86:303–6.

Kotler

Wang

Pierson

. Body composition studies in patients with AIDS. Am J Clin Nutr 1985;42:1255–65.

Perelson

Essunger

Cao

. Decay characteristics of HIV-1 components during combination therapy. Nature 1997;387:188–91.

Rosenberg

Billingsley

Caliendo

Boswell

Sax

Kalams

Vigorous HIV-1 specific CD4 T-cell responses associated with control of viremia. Science 1997;278:1447–50.

Patella

Delanney

Moorman

Loveless

Fuhrer

Satten

Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998;338:853–60.

10.

Safrin

Grunfeld

. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999;13:2493–505.

11.

Hommes

MJT

Ramijn

Endert

Sauerwein

Schattenkerk

Eeftinck JK

. Insulin sensitivity and insulin clearance in human immunodeficiency virus—infected men. Metabolism 1991;40:651–6.

12.

Heylingenber

Romijn

Hommes

MJT

Endert

Schattenkerk

Eeftinck JKM

Sauerwein

. Non-insulin mediated glucose uptake in human immunodeficiency virus—infected men. Clin Sci 1993;84:209–16.

13.

Hellerstein

Grunfeld

Christiansen

Kaempfer

Kletke

Increased de novo hepatic lipogenesis in HIV infection. J Clin Endocrinol Metab 1993;76:559–65.

14.

Grunfeld

Pang

Doerrler

Shigenaga

Jensen

Feingold

. Lipids, lipoproteins, triglycerides clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045–52.

15.

Grunfeld

Kotler

Hamadeh

Tierney

Wang

Pierson

. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989;86:27–31.

16.

Hommes

MJT

Romijn

Endert

Schattenkerk

Eeftinck JKM

Sauerwein

. Basal fuel homeostasis in symptomatic human immunodeficiency virus infection. Clin Sci 1991;80:359–65.

17.

Grunfeld

Feingold

. The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 1991;3:143–58.

18.

Chang

Dulloo

Bistrian

. Role of cytokines in AIDS wasting. Nutrition 1998;14:853–63.

19.

Poli

Fauci

. The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection. Pathophysiology 1992;60:246–51.

20.

Gaillard

. Cytokines in the neuroendocrine system. Intern Rev Immunol 1998;17:181–216.

21.

Feingold

Grunfeld

. Tumor necrosis factor alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest 1987;80:184–90.

22.

Semb

Peterson

Tavernier

Olivecrona

. Multiple effects of tumor necrosis factors on the lipoprotein lipase in vivo. J Biol Chem 1987;62: 8390–4.

23.

Savastano

Tommaselli

Valentino

Scarpitta

D'amore

Luciano

Hypothalamic—pituitary—adrenal axis and immune system. Acta Neurologica 1994;16:206–13.

24.

Gaillard

. Pituitary—immune system interactions. In: Melmed

, ed. Molecular and clinical advances in pituitary disorders. A basic and clinical update. Beverly Hills: Endocrine Research and Education, 1993:87–92.

25.

Besedovosky

Del Rey

Sorkin

Dinarello

. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science 1986;233:652–4.

26.

Grunfeld

Feingold

. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:329–37.

27.

Feingold

Soued

Serio

. Multiple cytokines stimulate hepatic synthesis in vivo. Endocrinology 1989;125:267–74.

28.

Feingold

Grunfeld

. Role of cytokines in inducing hyperlipidemia. Diabetes 1992;41(suppl 2):97–101.

29.

Van Snick

. Interleukin-6: An overview. Ann Rev Immunol 1990;8:253–78.

30.

Martinez-Maza

. IL6 and AIDS. Res Immunol 1992;143:764–9.

31.

Koivisto

Pelkonen

Cantell

. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641–7.

32.

Grunfeld

Shigenaga

Doerrler

Tierney

Wang

Pierson

Circulating interferon-alpha level and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154–62.

33.

Evans

Argiles

Williamson

. Metabolic effects of tumor necrosis factor-alpha (cachectin) and interleukin-1. Clin Sci 1989;77: 357–64.

34.

Patton

Shepard

Wilking

. Interferons and tumor necrosis factor have similar catabolic effects on 3TC-L1 cells. Proc Natl Acad Sci 1986;83:8313–7.

35.

Miller

Daly

Sentochnik

Doweiko

Samore

Basgoz

Pseudo-Cushing syndrome in human immunodeficiency virus– Infected patients. Clin Infect Dis 1998;27:68–72.

36.

Azar

Melby

. Hypothalamic—pituitary—adrenal function in non-AIDS patients with advanced HIV infection. Am J Med Sci 1993;305:321–5.

37.

Norbiato

Bevilacqua

Vago

Baldi

Chebat

Bertora

Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:608–13.

38.

Chang

Cockran

. Drug-induced disturbances of carbohydrate metabolism. Adverse Drug React Toxicol Rev 1991;10:1–29.

39.

Seale

J P

Compton

. Side-effects of corticosteroid agents. Med J Aust 1986;144:139–42.

40.

Del Valle

Gonzalez L

Ambrosio

Hernandez

Diaz

Caballero

. Hyperglycemia induced by megestrol acetate in a patient with AIDS. Ann Pharmacother 1996;30:1113–4.

41.

Siminoski

Drucker

Goss

. The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med 1989;111:758–60.

42.

Pandit

Burke

Gustafon

Minochu

. Drug-induced disorders of glucose intolerance. Ann Intern Med 1993;118:529–39.

43.

Henry

Rathgaber

Sullivan

McCabe

. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992;116:53–4.

44.

Schwartz

Brandt

. The spectrum of pancreatic disorders in patients with AIDS. Am J Gastroenterol 1989;84:459–62.

45.

Kilby

Tabereaux

. Severe hyperglycemia in an HIV clinic: Preexisting versus drug-associated diabetes mellitus. J Acquir Immune Syndr Human Retrovirol 1998;17:46–50.

46.

Chen

Braham

Squires

. Diabetes after aerosolized pentamidine. Ann Intern Med 1991;114:913–4.

47.

Shen

Orwell

Cohn

Prince

. Pentamidine-induced pancreatic beta-cell dysfunction. Am J Med 1989;86:726–8.

48.

Monk

J P

Benfield

. Inhaled pentamidine: An overview of its pharmacological properties and a review of its use in PCP. Drugs 1990;39:741–56.

49.

Ravaux

Rihet

Quinson

Mars

Sellier

Gallais

. Relapse of pentamidine-induced diabetes in AIDS patients (abstract Mo.B.1189). In: Program and abstracts of the 11th World AIDS Conference, Vancouver, June 28–July 31, 1996.

50.

Vigouroux

Gharakhanian

Salhi

Nguyen

Adda

Rozenbaum

Adverse metabolic disorders during highly active antiretroviral treatments of HIV disease. Diabetes Metab 1999;25:383–92.

51.

Qaqish

Fisher

Rubbein

Wohl

. HIV-associated lipodystrophy syndrome. Pharmacotherapy 2000;20:13–22.

52.

Visnegarwala

Frause

Musher

. Severe diabetes associated with protease inhibitor therapy (letter). Ann Intern Med 1997;127:947.

53.

Eastone

Derker

. New-onset diabetes mellitus associated with use of protease inhibitors (letter). Ann Intern Med 1997;127:948.

54.

Dong

Gruta

Legg

. Diabetes and use of protease inhibitors (abstract). In: Program and abstracts of the 12th World AIDS Conference, Geneva, June 28–July 31, 1998.

55.

Carr

Samaras

Thorisdottir

Kaufman

Chisholm

Cooper

. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor—associated lipodystrophy, hyperlipidemia, and diabetes mellitus: A cohort study. Lancet 1999;353:2093–9.

56.

Dube

M P

Johnson

Currier

Leedom

. Protease inhibitor—associated hyperglycemia (letter). Lancet 1997;350:713–4.

57.

Gharakhanian

Salhi

Nguyen

Adda

Catrix

Vigouroux

Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors (abstract 642). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4, 1999.

58.

Martinez

Garcia

Conget

Buira

Blanco

Mallolas

Incidence, characteristics, and prognosis of diabetes mellitus associated with protease inhibitors. 7th Conference on Retroviruses and Opportunistic Infections (abstract 16). San Francisco, January 30–February 2, 2000.

59.

Paterson

. Exacerbated hyperglycemia associated with nelfinavir. Ann Pharmacother 1998;32:609–10.

60.

Dube

Johnson

DLJ

Currier

JSC

Leedom

JML

. Protease inhibitor– Associated hyperglycemia: results of switching from indinavir to nelfinavir (abstract 32172). 12th World AIDS Conference, Geneva, June 28–July 3, 1998.

61.

Data on file, GlaxoWellcome Inc. (RM 1998/00318/00 integrated summary of safety).

62.

Pedneault

Hanson

Nacci

. Amprenavir: a new protease inhibitor with a favorable metabolic profile (abstract 34). 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June 26–28, 1999.

63.

Mulligan

Grunfeld

Tai

Algren

Pang

Chernoff

. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Syndr Human Retrovirol 2000;23:35–43.

64.

Al-Harthi

Roebuck

Kessler

Landay

. Inhibition of cytokine-driven human immunodeficiency virus type I replication by protease inhibitor. J Infect Dis 1997;176:1175–9.

65.

Carr

Samaras

Chisholm

Cooper

. Pathogenesis of HIV-1-protease inhibitor—associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881–3.

66.

Walli

Herfort

Michl

Demant

Jager

Dieterle

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167–73.

67.

Goebel

Walli

. Antiretroviral therapy-associated insulin resistance: frequency, potential causes and possible therapeutic interventions. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (abstract 005). San Diego, June 26–28, 1999.

68.

Reaven

. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607.

69.

Behrens

Dejam

Schmidt

Balks

Brabant

Korner

. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63–70.

70.

Saad

Knowler

Pettitt

Nelson

Charles

Bennet

. A two-step model for the development of non-insulin– Dependent diabetes. Am J Med 1991;90:229–35.

71.

Yarasheski

Tebas

Sigmund

Dagogo-Jack

Bohrer

Turk

Insulin resistance in HIV protease inhibitor—associated diabetes. J Acquir Immune Syndr Human Retrovirol 1999;21:209–16.

72.

Saint-Marc

Poizot-Martin

Partisani

Fabre

Touraine

Bruno

. A syndrome of lipodystrophy in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1659–67.

73.

Madge

Loes

Kinloch-De S

Tyrer

Jonhson

. Lipodystrophy syndrome in patients on reverse transcriptase inhibitors (abstract 654). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4, 1999.

74.

Carr

Miller

Law

Cooper

. A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside reverse transcriptase inhibitor therapy: contribution to protease inhibitor– Related lipodystrophy syndrome (abstract 011). 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June 26–28, 1999.

75.

Goujard

Lescaux

Dulioust

Boue

Delfraissy

Sobel

Lipodystrophy in protease inhibitor—naïve patients treated with reverse transcriptase inhibitor combinations: frequency and risk factors (abstract 20). 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30–February 2, 2000.

76.

Modina

Angelini

Cotte

Lang

Morlat

Rancinan

Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside reverse transcriptase inhibitors, ALBI trial (ANRS070) (abstract 19). 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, January 30-February 2, 2000.

77.

Brinkman

Burger

Smeitink

JAM

Koopmans

Ter Hofstede

HJM

. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 1998;12:1735–44.

78.

Kakuda

Brundage

Anderson

Fletcher

. Nucleoside reverse transcriptase inhibitor—induced mitochondrial toxicity as an etiology for fat redistribution syndrome (abstract 041). 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, June 26–28, 1999.

79.

American Diabetes Association: Clinical practice recommendations. Diabetes Care 1996;19(suppl 1):S1–118.

80.

American Diabetes Association. Consensus Development Conference on Insulin Resistance. Diabetes Care 1998;21:310–4.

81.

American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care 1999;22(suppl 1):S49–53.

82.

Summary of the second report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 1993;269:3015–23.

83.

Martinez

Conget

Lozano

Casamitjana

Gatell

. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805–10.

84.

Moyle

Baldwin

Dent

Gazzard

. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons (abstract 669). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4, 1999.

85.

Scheen

Lefebvre

. Oral antidiabetic agents. A guide to selection. Drugs 1998;55:225–36.

86.

Saint-Marc

Touraine

. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy (abstract 672). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, January 31–February 4, 1999.

87.

Package insert. Glucophage (metformin hydrochloride). Princeton, NJ: Bristol-Myers Squibb, January 1999.

88.

Saltiel

Olefsky

. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996;45:1661–9.

89.

US Department of Health and Human Services. Food and Drug Administration. Rezulin to be withdrawn from the market. March 21, 2000.

90.

Forman

Simmons

Diamond

. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118–21.

91.

Al-Salman

Arjomand

Kemp

Mittal

. Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med 2000;132:121–4.

92.

Package insert. Actos (pioglitazone). Indianapolis, IN: Eli Lilly, July 1999.

93.

Package insert. Avandia (rosiglitazone). Philadelphia: SmithKline Beecham Pharmaceuticals, 1999.